Atlas›Domain XII · Complementary, energy & biofield›Guide 154
Guide XII-154

Essiac

Rene Caisse1922Canada
A 33 · L 54 · M 1312 interventions in the Trinity explorer
Client cardCompare
[source: …] where a claim comes from[uncertain] not confirmed in a primary source[synthesis] the writer's reconstruction

1. What it was

Version followed: the four-herb Essiac associated with the Ontario nurse Rene Caisse (clinic era 1930s to early 1940s, then Canadian compassionate-access and investigational era to the 1980s) and its commercial successors, including the eight-herb Flor Essence, as described by the US National Cancer Institute (NCI) PDQ summary, Memorial Sloan Kettering (MSK) About Herbs, Cancer Research UK, CAM-Cancer (NAFKAM) and an archival history by Barbara Clow in Archivaria. This is a historical account written so clinicians can recognise the product and the decisions around it; it is not presented as a treatment for cancer or any other disease, and no therapist role exists in giving, recommending or selling it.

Who, where, when.

  • Rene Caisse was born in Bracebridge, Ontario (1888) and trained as a nurse in Ontario and Connecticut [source: Clow, Archivaria].
  • In 1922 she obtained a herbal formula from a patient who said it had cured her breast cancer; the patient reportedly had it from an Ontario Ojibwa healer [source: NCI PDQ; Clow describes the healer as a Native Canadian healer]. The Indigenous origin is a claim attributed by these accounts; the original healer and formula are not documented [uncertain].
  • The name is Caisse's surname spelled backwards [source: Cancer Research UK; Clow].
  • Early use included treating a relative with inoperable stomach cancer around 1924, with an attending physician involved in testing until about 1926 [source: Clow].
  • Bracebridge town council offered her the former British Lion Hotel in 1935 and she ran a cancer clinic there, giving the remedy free [source: Clow; NCI PDQ]. Clow's footnotes cite local newspaper reports of the clinic closing in May 1938 when a new provincial law took effect, and of Caisse closing the clinic in January 1941, and her text says Caisse decided to retire in 1942 [source: Clow]. Other summaries compress this: NCI gives the clinic as 1934 to 1942; CAM-Cancer says it closed in 1941 after intervention by Canadian authorities [source: NCI PDQ; CAM-Cancer]. The exact span of operation therefore varies by source [uncertain: sources differ].
  • After the clinic closed she continued supplying Essiac until the late 1970s; from 1959 she worked with an American physician on studies that led to the eight-herb Flor Essence, none published in peer-reviewed journals [source: NCI PDQ]. Clow reports that Elaine Alexander claimed to have acquired a later version from Charles Brusch in 1988 and marketed it as Flor Essence through Flora Distributors [source: Clow].
  • In 1977 Caisse passed a four-herb recipe to a Canadian company (spelled Respirin by Clow, Resperin in NCI references), reportedly for a small sum; she died in December 1978 [source: Clow; NCI PDQ]. That company dissolved in 1995 and a new company was formed to market the mixture; CAM-Cancer names David Dobbie as buying the formula and trademark in 1995 [source: NCI PDQ; CAM-Cancer]. Essiac is now a registered trademark held by Essiac Canada International [source: Cancer Research UK].

Ingredients (names only). Essiac: burdock root, Indian rhubarb root, sheep sorrel, slippery elm inner bark. Flor Essence adds watercress, blessed thistle, red clover and kelp [source: NCI PDQ; Cancer Research UK]. Brand names include Essiac, Vitaltea and Flor-Essence [source: MSK]; CAM-Cancer reports more than 40 formulas sold worldwide [source: CAM-Cancer].

Stated rationale and how it was sold.

  • To patients: a cure or control for cancer ("the tea of life"), immune support, symptom relief, "detoxification", and, for people told their cancer cannot be cured, the hope of living longer [source: Cancer Research UK]. Uses also promoted for HIV/AIDS and as a general tonic [source: MSK].
  • Evidence for the cure narrative was testimonial. Caisse estimated about 1,500 patients treated by 1938 but produced 84 case histories, many incomplete and anecdotal, when the province asked for proof [source: Clow].
  • Secrecy was central. Caisse refused to disclose the formula to the Ontario government's investigators, which stalled the 1935 to 1940 evaluation efforts; Clow quotes her: "I thought if I cured enough people that it could not be disputed." [source: Clow].
  • To referrers and regulators: from 1978 the company obtained Canadian permission for clinical study; this was withdrawn in 1982 for failure to meet commitments on manufacturing control, characterising active substances and trial design; a US New Drug Application was unsuccessful [source: NCI PDQ]. Physicians could request it for patients under Canada's Emergency Drug Release (Special Access) Programme; promotion as a cancer treatment was restricted, and that access has since been discontinued [source: NCI PDQ].
  • In the 1980s, Essiac-like products moved to being marketed as "health tonics" rather than drugs, which took them outside drug regulation [source: NCI PDQ]. Today Essiac is not licensed as a medicine and is usually sold as a nutritional supplement [source: Cancer Research UK; CAM-Cancer].

Status in one line each. Regulatory: not FDA-approved for cancer or any condition; not a licensed medicine in Canada or the UK [source: NCI PDQ; CAM-Cancer; Cancer Research UK]. Evidence: no peer-reviewed clinical trial; mouse tumour testing at MSK in the 1970s to 1980s and at NCI in 1983 found no anticancer activity [source: NCI PDQ]; MSK states it "has not been shown to treat or prevent cancer" [source: MSK].

2. What was actually done

Selection and arrival (clinic era). People with cancer, often advanced or after conventional treatment, came to the Bracebridge clinic in growing numbers; Clow describes queues of sufferers outside her door [source: Clow]. There is no source describing a formal diagnostic assessment or selection criteria at the clinic [uncertain].

Consent and pressure. The remedy was given free during the clinic years [source: NCI PDQ], which framed it as charity rather than commerce. No record describes information about lack of evidence being given; the formula itself was kept secret, so patients could not know what they were taking [source: Clow; inference from secrecy: synthesis].

Components as patients experienced them.

  • Injection: historically, one of the herb extracts was injected at or near tumour sites [source: NCI PDQ].
  • Oral tea: the other herbs were taken by mouth as a herbal tea [source: NCI PDQ].
  • CAM-Cancer reports that in 1938 concern arose after a reported death and a toxicity report following Essiac injections [source: CAM-Cancer] [uncertain: secondary; no primary record cited].

Compassionate-access and trial era (late 1970s to 1980s). Doctors requested supply for individual patients. The investigational trial was not randomised, had no controls, and treatment was usually given at patients' own request; it was judged inconclusive and cancelled [source: Clow]. A government review of physician-submitted case summaries (86 or 87 patients) found 47 had no benefit, 17 died and 8 could not be evaluated; of 8 followed further, 2 died, 3 had progressive disease and 3 were stable, those 3 having had prior conventional therapy [source: NCI PDQ; CAM-Cancer].

Commercial era (1980s to now). Bought by consumers as dried tea, powders, liquid extracts, capsules or drops [source: Cancer Research UK; CAM-Cancer]. Manufacturers attach rules about meal timing and an uninterrupted multi-week course [source: Cancer Research UK; NCI PDQ] (quantities and schedules deliberately omitted here). Some product literature told patients that no other treatment, including chemotherapy and radiotherapy, should be used while taking it [source: CAM-Cancer]; makers elsewhere say it can be used alongside cancer treatment, while some websites advise stopping treatment [source: Cancer Research UK].

How progress was judged. By testimony and anecdote: reports of disappearing cancers usually lacked diagnostic detail or information about the conventional treatment received [source: Cancer Research UK; Clow].

Non-response or refusal. No source describes a protocol for non-response [uncertain]. Manufacturer-listed reactions to Flor Essence (more frequent bowel movements or urination, swollen glands, skin blemishes, flu-like symptoms, mild headaches) were presented as expected effects [source: NCI PDQ; MSK]; whether these were framed to users as signs of "cleansing" is [uncertain].

Named variants. Essiac (four herbs); Flor Essence (eight herbs); Vitaltea; many unbranded "Essiac-type" or "essiac tea blends", including blends with cat's claw sold by the Native Essence Herb Company [source: MSK; CAM-Cancer; FTC].

3. How it caused harm

Delay or abandonment of effective cancer treatment. Mechanism: a person with a treatable cancer replaces or postpones surgery, chemotherapy, radiotherapy or hormone therapy. Cancer Research UK warns that stopping these could be very harmful [source: Cancer Research UK]. Product literature telling users to avoid all other treatment adds direct pressure [source: CAM-Cancer]. The Canadian government's stated concern was that even harmless remedies like Essiac divert patients from conventional care [source: Clow]. General evidence (not Essiac-specific): among people with non-metastatic breast, prostate, lung or colorectal cancer in the US National Cancer Database (2004 to 2013), those who chose alternative medicine alone had a substantially higher risk of death (overall hazard ratio 2.50; breast 5.68; colorectal 4.57; lung 2.17; prostate not significant) [source: Johnson et al. 2018, JNCI].

Drug interactions. Essiac inhibits cytochrome P450 enzymes in vitro, and a case report found raised blood levels of an experimental camptothecin chemotherapy drug, with potential for added toxicity; MSK advises not taking it during chemotherapy [source: MSK; Cancer Research UK]. Individual herbs carry bleeding-risk concerns with anticoagulants (burdock, red clover, kelp), red clover may interfere with tamoxifen, and kelp may induce or worsen hyperthyroidism [source: CAM-Cancer].

Direct adverse effects. Nausea and vomiting are the only effects reported for Essiac itself [source: NCI PDQ]. A case report describes a woman with loss of appetite, nausea, muscle pain, fatigue and abdominal pain after months of use, resolving when she stopped [source: MSK; Cancer Research UK]. Herb-specific risks: rhubarb cramps, watery diarrhoea and electrolyte loss with chronic use; burdock allergy, rarely anaphylaxis, and low blood sugar in animal models; slippery elm whole bark described as an abortifacient when taken orally [source: CAM-Cancer; MSK]. CAM-Cancer concludes the safety profile is "largely unknown" [source: CAM-Cancer].

Possible tumour stimulation. In laboratory studies Essiac and Flor Essence stimulated breast cancer cell growth through oestrogen-receptor-dependent and independent pathways; in a rat study, Flor Essence groups had higher mammary tumour incidence than controls [source: NCI PDQ; MSK].

Psychological and relational harm. False hope and later regret; in a breast-cancer survey, users generally scored worse on quality-of-life measures and the authors suggested Essiac use is "a marker of physical distress" [source: CAM-Cancer summarising Zick et al. 2006]. Family conflict and guilt after a death where treatment was declined are clinically expected but not documented in Essiac-specific sources [synthesis].

Financial harm and deceptive marketing. In 2009 the US Federal Trade Commission announced a proposed settlement with the Native Essence Herb Company and its principals Mark J. and Marianne Hershiser over unsubstantiated claims that essiac tea blends and other products treated and cured cancers, shrank tumours and prevented breast cancer, including false claims of scientific proof; the order required notifying past buyers to consult a medical professional [source: FTC 2009]. Cancer Research UK advises caution about paying for alternative cancer therapies found online [source: Cancer Research UK].

Who was most at risk. People with curable cancers who forgo treatment; people with advanced cancer seeking hope after being told cure is not possible; people on chemotherapy, anticoagulants or tamoxifen; people with hormone-sensitive breast cancer; pregnant or breastfeeding women (Flor Essence makers advise against use) [source: NCI PDQ; Cancer Research UK; MSK; CAM-Cancer]. Children: the rat findings raise a theoretical concern about mammary development in childhood, although the manufacturer says children may use Flor Essence [source: NCI PDQ].

4. Recognising it today

Names and forms. Essiac, Essiac tea, Flor Essence or Flor-Essence, Vitaltea, "eight-herb" or "four-herb" tea, and generic "essiac tea blends", sometimes combined with other herbs such as cat's claw [source: MSK; NCI PDQ; FTC]. Sold as dried tea, powder, liquid extract, capsules or drops, mostly online and in health-food outlets [source: Cancer Research UK; CAM-Cancer].

Phrases and rationales that signal it.

  • "The tea of life"; claims that it cures or controls cancer, "detoxifies", strengthens the immune system or eases pain, weight loss and fatigue [source: Cancer Research UK].
  • Origin stories of a secret Ojibwa or Native formula passed to a nurse, with testimonies of cures [source: NCI PDQ; Clow]. Clients may value the Indigenous connection; respect that meaning while noting the formula's commercial history [synthesis].
  • Narratives that authorities blocked the remedy: the historical record shows the Ontario investigation stalled because the formula was withheld [source: Clow]; a "suppressed cure" framing is a common marketing pattern [synthesis].
  • One product claimed to treat many cancers, shrink tumours or prevent breast cancer, and "scientifically proven" claims without studies [source: FTC 2009].
  • Labelling as a tonic or supplement while cancer claims circulate on websites, testimonials or forums [source: NCI PDQ; Cancer Research UK].
  • Instructions to avoid chemotherapy or radiotherapy while taking it, or to stop treatment [source: CAM-Cancer; Cancer Research UK].

Clinical cues in the client. Mentions of a herbal tea for cancer; new gastrointestinal symptoms, fatigue or appetite loss attributed to "cleansing"; missed oncology appointments; reluctance to tell the oncologist about supplements; spending on online remedies; distress that drives searching for alternatives (Essiac use was linked to physical distress in one survey) [source: CAM-Cancer; synthesis for the clinical cues].

Red flags in a colleague's or a service's practice [synthesis unless cited].

  • Recommending, selling, stocking or receiving commission on Essiac or similar products, or linking to sellers.
  • Presenting it as a cancer treatment, an immune booster or a detox, or telling clients it is "natural so safe" (contradicted by interaction data) [source for interactions: MSK].
  • Advising a client to delay or decline oncology treatment, or not to tell their doctor.
  • Testimonial-based case claims; certification or training businesses built around a remedy.

How legitimate practice differs. Integrative oncology uses complementary approaches alongside, never instead of, standard treatment, with the oncology team informed (see 172) [synthesis]. Investigational products are legitimately accessed through regulated clinical trials with an approved protocol; NCI notes none has been announced for Essiac or Flor Essence [source: NCI PDQ]. The psychotherapist's legitimate role is conversation, decision support and coordination, never product advice [synthesis].

5. What to do instead and how to help those harmed

Recommended alternatives. Evidence-based oncology care from the treating team; integrative oncology delivered alongside it (entry 172); palliative and supportive care for symptoms and quality of life; psycho-oncology and psychological support for distress, fear and decision-making; for people seeking investigational options, regulated clinical trials [source: Cancer Research UK advises talking to the cancer specialist and not replacing treatment; NCI PDQ on trials; remainder synthesis]. Health anxiety and somatic symptom presentations are addressed with established approaches (cross-reference Domain II) [synthesis].

The psychotherapist never performs, sells, prescribes or recommends Essiac or any remedy, and never advises starting, stopping or changing a medicine or remedy; those questions go to the oncologist, prescriber or pharmacist [synthesis].

Asking about remedy use routinely and without judgement

  • Purpose: surface use early, because patients often do not tell their doctors; MSK and Cancer Research UK both advise telling the care team about all supplements [source: MSK; Cancer Research UK].
  • Steps: ask every client with cancer, and family members of people with cancer, about teas, herbs, supplements and "natural" treatments as part of the health history; use open, neutral wording; record product name, source, who suggested it and whether the treating team knows; revisit at treatment transitions [synthesis].
  • Example language (illustrative): "Many people with cancer try herbal teas or supplements. Is there anything like that you are taking or thinking about?" / "Does your oncology team know about it?"
  • Watch for: defensive answers that suggest expected disapproval; vague "just a tea" replies; use hidden from family or doctor. It is working when the client discusses use openly and agrees to share it with the team [synthesis].

Exploring meaning, hopes and the client's explanatory model

  • Purpose: understand what draws the client: control, hope after hearing cancer cannot be cured, distrust of medicine, fear of side effects, a family or community recommendation, or valuing an Indigenous-origin story [source: Cancer Research UK on hope for longer life; remainder synthesis].
  • Steps: invite the client's own story of the illness and what they believe Essiac does; reflect the underlying need (hope, agency, safety); separate the need from the product; check what outcome they expect and by when; note distress, since use has been described as a marker of physical distress [source: CAM-Cancer for distress; steps synthesis].
  • Example language (illustrative): "What do you hope the tea will do for you?" / "It sounds like having something you can do yourself matters a great deal right now."
  • Watch for: expectations of cure; an all-or-nothing stance against conventional treatment; despair masked as certainty. It is working when the client names the underlying need and is open to other ways of meeting it [synthesis].

Autonomy-respecting decision support

  • Purpose: help the client make an informed, values-based decision without coercion; Cancer Research UK states that only the patient can decide whether to try it [source: Cancer Research UK].
  • Steps: clarify the decision actually on the table (adding a product vs replacing or delaying treatment); help the client gather accurate information from the oncology team and reputable sources such as the NCI PDQ, MSK About Herbs and Cancer Research UK pages; explore values, fears and trade-offs; check understanding; respect the choice and keep the relationship open. No specific published decision aid is endorsed here [synthesis; sources named are those cited in this guide].
  • Example language (illustrative): "Could we look at what you would be choosing between, and what matters most to you in that choice?" / "Whatever you decide, I will still be here to talk it through."
  • Watch for: the therapist drifting into persuasion or into product advice; client capacity under severe distress, delirium or depression (assess and involve the medical team if capacity is in doubt). It is working when the client can state the options and their own reasons [synthesis].

Coordination with the oncologist, doctor and pharmacist

  • Purpose: ensure interaction and safety questions reach those qualified to answer; MSK warns against use during chemotherapy and Cancer Research UK advises discussing liver-enzyme effects with the cancer specialist [source: MSK; Cancer Research UK].
  • Steps: with consent, encourage the client to tell the oncology team, or offer a joint letter or call; share only what is needed; route all questions about stopping, starting or combining products to the prescriber or pharmacist; document consent and contacts [synthesis].
  • Example language (illustrative): "Some herbal products can change how cancer drugs work, so your oncologist or pharmacist needs to know. Would you like help raising it at your next appointment?"
  • Watch for: the client asking the therapist whether to stop the tea or the chemotherapy (redirect to the prescriber); refusal of consent to share (respect it unless a safeguarding threshold is met). It is working when the treating team is aware and the client feels supported rather than reported on [synthesis].

Responding when a client delays or declines conventional treatment

  • Purpose: reduce the risk of the most serious harm, abandonment of effective treatment, which is linked to a substantially higher risk of death in curable cancers [source: Johnson et al. 2018; Cancer Research UK].
  • Steps: name the risk plainly and once, without lecturing; explore what drives the refusal (fear of side effects, past bad experiences, mistrust); encourage a second oncology opinion or a conversation about modified options; agree that the client will keep oncology appointments even while deciding; document the discussion and the client's decision; consult supervision [synthesis].
  • Example language (illustrative): "I respect that this is your decision. I would be letting you down if I did not say that the evidence suggests delaying treatment can be dangerous. Could we think about what would make it easier to keep talking with your oncologist?"
  • Watch for: product literature telling the client to avoid all other treatment [source: CAM-Cancer]; external pressure from sellers or groups; sudden withdrawal from therapy. It is working when the client stays connected to the oncology team, whatever the choice [synthesis].

Supporting hope and palliative referral in advanced illness

  • Purpose: some people turn to Essiac after hearing their cancer cannot be cured, hoping to live longer [source: Cancer Research UK]; meet that hope with care rather than argument.
  • Steps: acknowledge the hope; explore what "living well" would mean now; with consent, suggest or support referral to palliative and supportive care for symptoms the client hopes the tea will ease (pain, weight loss, low energy); attend to anticipatory grief [synthesis].
  • Example language (illustrative): "It makes sense to want to try everything. Alongside that, would it help to talk with the palliative care team about your energy and pain?"
  • Watch for: collusion with unrealistic expectations versus crushing hope; caregiver burnout. It is working when symptom needs are addressed and conversations about goals become possible [synthesis].

Grief, regret and guilt after choosing an alternative

  • Purpose: support clients, or bereaved family members, who believe that choosing Essiac instead of or before treatment contributed to progression or death [synthesis].
  • Steps: assess for complicated grief, depression and suicidal ideation using standard risk assessment; separate hindsight knowledge from what was known and believed at the time; work with self-blame and anger at sellers or at medicine; allow ambivalence; consider grief-focused or trauma-informed approaches as clinically indicated [synthesis].
  • Example language (illustrative): "You made that choice out of love and the information you had then. Can we look at what you knew at the time, rather than what you know now?"
  • Watch for: persistent self-blame, hopelessness or suicidal thoughts (follow standard suicide risk assessment and safety planning); blaming within the family. It is working when the client can hold regret without self-condemnation [synthesis].

Family conflict

  • Purpose: manage disagreement when one person wants the remedy and others want conventional care, or when relatives purchase or push products [synthesis].
  • Steps: with consent, hold a family meeting focused on the patient's values and wishes; validate each member's fear; agree roles (who attends appointments, who handles information); refer to the oncology or palliative team's family meeting where available [synthesis].
  • Example language (illustrative): "Everyone here wants the same thing, for your mother to be as well as possible. Can we hear from her what matters most?"
  • Watch for: coercion in either direction; an adult patient's autonomy being overridden; caregivers' unspoken grief. It is working when the family can discuss the plan without rupture [synthesis].

Financial harm and exploitation

  • Purpose: address money lost to products sold with false cancer claims, as in the FTC's essiac tea blends case [source: FTC 2009; Cancer Research UK].
  • Steps: ask about spending, including any crowdfunding or family fundraising, without shame; look for escalating purchases, subscription traps or pressure from sellers or online groups; help the client consider complaint and refund routes; consider adult safeguarding if a person at risk is being exploited [synthesis].
  • Example language (illustrative): "Some sellers make promises that are not true. Has paying for these products put pressure on you or your family?"
  • Watch for: shame preventing disclosure; continued buying despite harm. It is working when the client sets limits or seeks redress [synthesis].

Safeguarding children and adults at risk

  • Purpose: protect a child whose parents give the product in place of medical cancer treatment, or an adult at risk who is pressured to stop treatment [synthesis].
  • Steps: treat refusal of effective treatment for a child with cancer as a possible medical-neglect concern and follow local child-protection procedures; involve the child's treating team; consider the child's assent and views according to age and maturity, while parents and clinicians hold consent; for adults, assess capacity and coercion [synthesis]. Note the theoretical concern about effects on mammary development in childhood [source: NCI PDQ].
  • Example language (illustrative): "I can hear how much you want to protect your child. Because their treatment is involved, I need to talk with their medical team, and I want to do that with you."
  • Watch for: missed paediatric oncology appointments; secrecy; group or seller influence on parents. It is working when the child's care team is engaged [synthesis].

Managing the therapist's own boundaries and conflicts of interest

  • Purpose: keep the therapist's role clean [synthesis].
  • Steps: never sell, recommend or supply remedies or courses; disclose and avoid any financial link to sellers; keep personal views on remedies out of the session; seek supervision when personal experience of cancer is activated [synthesis; professional ethics codes on competence and conflicts of interest apply].
  • Example language (illustrative): "My role is not to advise on remedies. I can help you think it through and connect with the people who can answer the medical questions."
  • Watch for: clients asking for the therapist's endorsement; the therapist feeling pulled to rescue or to argue. It is working when the client brings product questions to their medical team [synthesis].

Reporting

  • Purpose: act on false cancer claims, adverse events and unsafe practice [synthesis].
  • Steps: with consent, encourage reporting suspected adverse effects to the prescriber and the national product regulator (Health Canada, the US FDA, the UK MHRA or equivalent); report deceptive cancer-cure marketing to consumer and advertising regulators such as the US FTC, whose action against sellers of essiac tea blends shows such claims are enforceable [source: FTC 2009; specific reporting forms and portals [uncertain]]; report a registered practitioner who promotes it as a cancer treatment to their professional or licensing board; make safeguarding referrals where thresholds are met [synthesis].
  • Example language (illustrative): "What happened to you may also happen to others. Would you want to report the seller? I can help you think about how."
  • Watch for: client fear of retaliation from a seller or group; confidentiality limits (explain before reporting). It is working when the client feels agency rather than further exposure [synthesis].

Handling problems [synthesis]. If the client disengages when the topic arises, slow down and return to meaning and hope rather than evidence. If the therapy relationship ruptures because the client feels judged, acknowledge it directly and restate respect for their autonomy. If a client continues use against medical advice, keep coordinating and document; continuation is their decision unless a child or adult-at-risk threshold is met.

Sources

← Previous · XII-153Hoxsey herbal treatmentNext · XII-155 →Black salve and escharotics